Applied Therapeutics Shares Are Trading Lower After the Company Announced That the FDA Extended the Review Period for the NDA for Govorestat for the Treatment of Classic Galactosemia by Three Months
應用療法公司宣佈,美國食品藥品管理局將Govorestat治療經典半乳糖血症的保密協議的審查期延長了三個月,此後,該公司股價走低